BCR-ABL Mutation Analysis
Sequencing
Indication
For initial detection and for monitoring of the mutational status of the BCR-ABL gene in CML patients who have developed resistance to imatinib or other kinase inhibitors.
Methodology
The presence of point mutations in the kinase domain of the BCR-ABL gene (codons 221-500) is assessed by direct Sanger sequencing of the bcr-abl fusion transcripts following nested PCR.
Test Parameters
The result will include the codon number, amino acid changes and relative abundance of the mutation(s) found. This test will detect mutated transcript that comprise at least 10% of total BCR-ABL fusion transcripts in sample.
Turnaround Time
10 days
Sample Requirements
- 10 mls peripheral blood (PB) in purple top tube (EDTA Vacutainer), sent on wet ice
or - 2-5 ml of bone marrow aspirate (BM), sent on wet ice
or - 20 µg of purified RNA, sent on dry ice
or - 10 µg of cDNA, sent on dry ice
CPT Codes
83891 (RNA Isolation), 83902, 83898 x 2, 83904x2, 83912
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.